Philips Respironics must hire an independent safety expert, undergo regular facility inspections for at least five years and pay part of its revenue to the federal government under an agreement with prosecutors filed in federal court in Pittsburgh on Thursday that caps one of the most catastrophic medical device recalls in decades.
The company also will have to undergo a review of its testing on the millions of replacement sleep apnea machines it sent to customers after the old ones were recalled in 2021.
The consent decree with the Justice Department comes nearly three years after Philips acknowledged that an industrial foam fitted inside its widely used sleep apnea machines and ventilators to reduce noise could degrade and release toxic particles and fumes into masks worn by patients.
A Pittsburgh Post-Gazette and ProPublica investigation last year found the medical device giant had withheld thousands of complaints about the degrading foam for more than a decade before warning its customers — including medically vulnerable patients, such as infants and the elderly — about the dangers.
The news organizations also revealed that a new, silicone-based foam that the company used in the replacement machines was also found to emit dangerous chemicals, including formaldehyde, a known carcinogen.
Though Philips maintained that the new foam was safe, scientists involved in the testing raised alarms, and the Food and Drug Administration said more tests were needed before determining if the devices pose “risks to patients.”
Read More
The consent decree requires Philips to carry out additional tests if the expert brought on by the company determines that prior testing was inadequate.
The agreement also prohibits Philips from selling all sleep apnea devices and other respiratory machines in the United States. In January, Philips disclosed that it would no longer distribute the machines in the country as part of the negotiations with the Justice Department – a major shift for a company that long dominated the industry.
Philips, which manufactures the devices at two plants outside Pittsburgh, is still able to export devices to other countries under the agreement. The company can also sell a select group of machines deemed “medically necessary” by the FDA in the United States, including some ventilators, but must turn over up to 25% of the revenue to the government.
The payments “are an equitable remedy and not punitive,” according to the agreement.
In the consent decree, the Justice Department argued that the company had violated federal law by selling “adulterated” machines that did not comply with manufacturing requirements. The agreement was signed by Roy Jakobs, chief executive officer of Philips’ parent company, Royal Philips, headquartered in Amsterdam. The company did not admit fault.
If Philips fails to abide by the agreement, it could be forced to pay up to $20 million a year.
Philips did not respond to questions about the consent decree, which still has to be approved by a judge.
The company has previously said that tests on the original foam caused no “appreciable harm” to patients. And in an online video about the settlement, chief patient safety and quality officer Steve C de Baca said the silicone-based foam in the replacement machines was safe.
Philips “[has] not identified any safety issues” with the replacement machines, and “their use is not impacted” by the consent decree, he said.
On an informational page for customers, Philips said the settlement with U.S. authorities will help it "restore the business.” The company also said it has launched multiple safety reforms.
The FDA said it would not comment until the settlement has been approved by the court. A Justice Department spokesperson declined to comment.
Federal investigators are also conducting a criminal inquiry. Documents related to the company’s testing have been turned over to investigators, who have subpoenaed former employees and contractors, according to sources familiar with the probe.
Patient safety advocates say it will take years to assess the impact of devices on patient health. At the time of the recall, both Philips and the FDA described potential health risks including respiratory tract illnesses, headaches, nausea, and toxic and carcinogenic effects.
The FDA has reported receiving 561 reports of deaths associated with the machines since 2021. The Post-Gazette and ProPublica previously identified reports that described nearly 2,000 cases of cancer, 600 liver and kidney illnesses, and 17,000 respiratory ailments.
Though the company says the foam in the recalled devices does not lead to long-term harm, the material has repeatedly tested positive for genotoxicity, the ability of a chemical to cause cells to mutate, a process that can lead to cancer.
Michael Twery, former director of sleep disorders research at the National Institutes of Health, said it could be difficult for Philips to earn back the trust of its customers.
“If a manufacturer misleads [the] FDA, how do they re-establish integrity?” he said.
Correction: April 6, 2024. The story has been updated to correct the terms in which the company must turn over its revenue to the federal government. The update also clarifies the terms in which the company must carry on further testing of the silicone foam.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.